The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

Emergence of New ALK Mutations at Relapse of Neuroblastoma

(2014) Gudrun Schleiermacher et al.   JOURNAL OF CLINICAL ONCOLOGY

New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK

(2013) G. Barone et al.   CLINICAL CANCER RESEARCH

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells

(2013) Kamaraj Sattu et al.   FEBS Journal

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

The genetic landscape of high-risk neuroblastoma

(2013) Trevor J Pugh et al.   NATURE GENETICS

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

(2012) Teeara Berry et al.   CANCER CELL

Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis

(2012) Shizhen Zhu et al.   CANCER CELL

Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma

(2012) A. Cazes et al.   CANCER RESEARCH

ERK5: Structure, regulation and function

(2012) Gopika N. Nithianandarajah-Jones et al.   CELLULAR SIGNALLING

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

(2012) C Schönherr et al.   ONCOGENE

Synergy Study of the Inhibitory Potential of Red Wine Polyphenols on Vascular Smooth Muscle Cell Proliferation

(2012) Elena Kurin et al.   PLANTA MEDICA

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

(2011) Xianming Deng et al.   ACS Medicinal Chemistry Letters

Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein

(2010) Qingkai Yang et al.   CANCER CELL

Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy

(2010) T. Martinsson et al.   CANCER RESEARCH

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

(2010) S. De Brouwer et al.   CLINICAL CANCER RESEARCH

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells

(2010) C Schönherr et al.   ONCOGENE

Myc proteins as therapeutic targets

(2010) W C Gustafson et al.   ONCOGENE

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

(2008) Helena Carén et al.   BIOCHEMICAL JOURNAL

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE